Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    September 2017
  1. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    PubMed     Text format     Abstract available


  2. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    PubMed     Text format     Abstract available


  3. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    PubMed     Text format     Abstract available


  4. QUIST AJL, Inoue-Choi M, Weyer PJ, Anderson KE, et al
    Ingested nitrate and nitrite, disinfection by-products, and pancreatic cancer risk in postmenopausal women.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31055.
    PubMed     Text format     Abstract available


    August 2017
  5. HARTNETT KP, Ward KC, Kramer MR, Lash TL, et al
    The risk of preterm birth and growth restriction in pregnancy after cancer.
    Int J Cancer. 2017 Aug 24. doi: 10.1002/ijc.30914.
    PubMed     Text format     Abstract available


  6. BABIC A, Harris HR, Vitonis AF, Titus LJ, et al
    Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Int J Cancer. 2017 Aug 22. doi: 10.1002/ijc.31010.
    PubMed     Text format     Abstract available


  7. WU YH, Huang YF, Chang TH, Chou CY, et al
    Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30932.
    PubMed     Text format     Abstract available


  8. CHEN T, Brenner H, Fallah M, Jansen L, et al
    Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30930.
    PubMed     Text format     Abstract available


  9. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Text format     Abstract available


  10. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available


  11. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    PubMed     Text format     Abstract available


  12. MORCH LS, Dehlendorff C, Baandrup L, Friis S, et al
    Use of antidepressants and risk of epithelial ovarian cancer.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30919.
    PubMed     Text format     Abstract available


    July 2017
  13. WU AH, Pearce CL, Lee A, Tseng C, et al
    Timing of births and oral contraceptive use influences ovarian cancer risk.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30910.
    PubMed     Text format     Abstract available


  14. VACCARELLA S, Laversanne M, Ferlay J, Bray F, et al
    Cervical cancer in Africa, Latin America and the Caribbean, and Asia: Regional inequalities and changing trends.
    Int J Cancer. 2017 Jul 22. doi: 10.1002/ijc.30901.
    PubMed     Text format     Abstract available


  15. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Text format     Abstract available


  16. BOTTERI E, Stoer NC, Sakshaug S, Graff-Iversen S, et al
    Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
    Int J Cancer. 2017 Jul 7. doi: 10.1002/ijc.30878.
    PubMed     Text format     Abstract available


  17. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
    Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
    PubMed     Text format     Abstract available


  18. KRITSCH D, Hoffmann F, Steinbach D, Jansen L, et al
    Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30860.
    PubMed     Text format     Abstract available


  19. MASSAD LS, Hessol NA, Darragh TM, Minkoff H, et al
    Cervical cancer incidence after up to 20 years of observation among women with HIV.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30866.
    PubMed     Text format     Abstract available


    June 2017
  20. BIXEL K, Saini U, Bid HK, Fowler J, et al
    Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Int J Cancer. 2017 Jun 24. doi: 10.1002/ijc.30847.
    PubMed     Text format     Abstract available


  21. JAREID M, Licaj I, Olsen KS, Lund E, et al
    Does an epidemiological comparison support a common cellular lineage for similar subtypes of postmenopausal uterine and ovarian carcinoma? The Norwegian Women and Cancer Study.
    Int J Cancer. 2017 Jun 8. doi: 10.1002/ijc.30826.
    PubMed     Text format     Abstract available


    May 2017
  22. MATSUO K, Shimada M, Aoki Y, Sakamoto M, et al
    Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
    PubMed     Text format     Abstract available


  23. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
    Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
    Int J Cancer. 2017;140:2212-2219.
    PubMed     Text format     Abstract available


  24. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
    Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
    Int J Cancer. 2017;140:2092-2100.
    PubMed     Text format     Abstract available


    April 2017
  25. BEN KHEDHER S, Neri M, Papadopoulos A, Christiani DC, et al
    Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the International Lung Cancer consortium (ILCCO).
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30750.
    PubMed     Text format     Abstract available


  26. ROHNER E, Sengayi M, Goeieman B, Michelow P, et al
    Cervical Cancer Risk and Impact of Pap-based Screening in HIV-positive Women on Antiretroviral Therapy in Johannesburg, South Africa.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30749.
    PubMed     Text format     Abstract available


  27. VERDOODT F, Kjaer Hansen M, Kjaer SK, Pottegard A, et al
    Statin use and mortality among ovarian cancer patients: A population-based cohort study.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30738.
    PubMed     Text format     Abstract available


  28. BALTZER N, Sundstrom K, Nygard JF, Dillner J, et al
    Risk Stratification in Cervical Cancer Screening by Complete Screening History- Applying Bioinformatics to a General Screening Population.
    Int J Cancer. 2017 Apr 6. doi: 10.1002/ijc.30725.
    PubMed     Text format     Abstract available


  29. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Text format     Abstract available


    March 2017
  30. STALBERG K, Kjolhede P, Bjurberg M, Borgfeldt C, et al
    Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study - On behalf of the Swedish gynecological cancer group (SweGCG).
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30707.
    PubMed     Text format     Abstract available


  31. MEZEI AK, Armstrong HL, Pedersen HN, Campos NG, et al
    Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review.
    Int J Cancer. 2017 Mar 15. doi: 10.1002/ijc.30695.
    PubMed     Text format     Abstract available


  32. HO D, Drake TK, Smith-McCune KK, Darragh TM, et al
    Feasibility of clinical detection of cervical dysplasia using angle-resolved low coherence interferometry measurements of depth-resolved nuclear morphology.
    Int J Cancer. 2017;140:1447-1456.
    PubMed     Text format     Abstract available


  33. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
    Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
    PubMed     Text format     Abstract available


  34. VAN DEN BRANDT PA, Schulpen M
    Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
    Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
    PubMed     Text format     Abstract available


  35. COBURN SB, Bray F, Sherman ME, Trabert B, et al
    International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.
    Int J Cancer. 2017 Mar 3. doi: 10.1002/ijc.30676.
    PubMed     Text format     Abstract available


    February 2017
  36. SHI T, Wang P, Xie C, Yin S, et al
    BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30633.
    PubMed     Text format     Abstract available


    January 2017
  37. HALONEN PM, Jakobsson MI, Oskari Heikinheimo MA, Riska AE, et al
    Lichen sclerosus and risk of cancer.
    Int J Cancer. 2017 Jan 25. doi: 10.1002/ijc.30621.
    PubMed     Text format     Abstract available


  38. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
    Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
    PubMed     Text format     Abstract available


  39. BORCH KB, Weiderpass E, Braaten T, Jareid M, et al
    Physical activity and risk of endometrial cancer in the Norwegian Women and Cancer (NOWAC) Study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30610.
    PubMed     Text format     Abstract available


  40. FALCONER H, Yin L, Bellocco R, Altman D, et al
    Thyroid cancer after hysterectomy on benign indications: Findings from an observational cohort study in Sweden.
    Int J Cancer. 2017 Jan 19. doi: 10.1002/ijc.30606.
    PubMed     Text format     Abstract available


  41. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
    Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Int J Cancer. 2017;140:423-430.
    PubMed     Text format     Abstract available


  42. PRAESTEGAARD C, Jensen A, Jensen SM, Nielsen TS, et al
    Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies.
    Int J Cancer. 2017 Jan 7. doi: 10.1002/ijc.30600.
    PubMed     Text format     Abstract available


  43. BAILEY HD, Rios P, Lacour B, Guerrini-Rousseau L, et al
    Factors related to pregnancy and birth and the risk of childhood brain tumours: The ESTELLE and ESCALE studies (SFCE, France).
    Int J Cancer. 2017 Jan 5. doi: 10.1002/ijc.30597.
    PubMed     Text format     Abstract available


    December 2016
  44. TANG FH, Hsieh TH, Hsu CY, Lin HY, et al
    KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
    Int J Cancer. 2016 Dec 29. doi: 10.1002/ijc.30591.
    PubMed     Text format     Abstract available


  45. BRUSSELAERS N, Maret-Ouda J, Konings P, El-Serag HB, et al
    Menopausal hormone therapy and the risk of esophageal and gastric cancer.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30588.
    PubMed     Text format     Abstract available


  46. GARCIA-SANZ P, Trivino JC, Mota A, Perez Lopez M, et al
    Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
    Int J Cancer. 2016 Dec 20. doi: 10.1002/ijc.30573.
    PubMed     Text format     Abstract available


  47. AGERBAEK MO, Pereira MA, Clausen TM, Pehrson C, et al
    Burkitt lymphoma express oncofetal Chondroitin Sulfate without being a reservoir for placental malaria sequestration.
    Int J Cancer. 2016 Dec 20. doi: 10.1002/ijc.30575.
    PubMed     Text format     Abstract available


  48. CHEN W, Molijn A, Enqi W, Zhang X, et al
    The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
    Int J Cancer. 2016;139:2687-2697.
    PubMed     Text format     Abstract available


  49. FORTNER RT, Husing A, Kuhn T, Konar M, et al
    Endometrial cancer risk prediction including serum-based biomarkers: Results from the EPIC cohort.
    Int J Cancer. 2016 Dec 9. doi: 10.1002/ijc.30560.
    PubMed     Text format     Abstract available


  50. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
    To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
    PubMed     Text format     Abstract available


  51. JONES NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, et al
    Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinomas.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30537.
    PubMed     Text format     Abstract available


    November 2016
  52. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
    Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
    Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
    PubMed     Text format     Abstract available


  53. HABBEMA D, Weinmann S, Arbyn M, Kamineni A, et al
    Harms of Cervical Cancer Screening in the United States and the Netherlands.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30524.
    PubMed     Text format     Abstract available


  54. WAKEHAM K, Kavanagh K, Cuschieri K, Millan D, et al
    HPV status and favorable outcome in vulvar squamous cancer.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30523.
    PubMed     Text format     Abstract available


  55. TAINIO K, Jakobsson M, Louvanto K, Kalliala I, et al
    Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management.
    Int J Cancer. 2016;139:2353-8.
    PubMed     Text format     Abstract available


    October 2016
  56. WU S, Wang S, Fu Y, Tang W, et al
    A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of CEBP/beta and OCT1 complex to chromatin.
    Int J Cancer. 2016 Oct 28. doi: 10.1002/ijc.30490.
    PubMed     Text format     Abstract available


  57. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


  58. FELIX AS, Bower JK, Pfeiffer RM, Raman SV, et al
    High cardiovascular disease mortality following endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, End Results Database.
    Int J Cancer. 2016 Oct 14. doi: 10.1002/ijc.30470.
    PubMed     Text format     Abstract available


  59. PERES LC, Bandera EV, Qin B, Guertin KA, et al
    Dietary Inflammatory Index and Risk of Epithelial Ovarian Cancer in African American Women.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30467.
    PubMed     Text format     Abstract available


  60. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
    Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
    PubMed     Text format     Abstract available


  61. AARESTRUP J, Gamborg M, Tilling K, Ulrich LG, et al
    Childhood BMI growth trajectories and endometrial cancer risk.
    Int J Cancer. 2016 Oct 8. doi: 10.1002/ijc.30464.
    PubMed     Text format     Abstract available


  62. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
    Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
    Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
    PubMed     Text format     Abstract available


    September 2016
  63. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
    HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
    Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
    PubMed     Text format     Abstract available


  64. HARRIS HR, Titus LJ, Cramer DW, Terry KL, et al
    Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.
    Int J Cancer. 2016 Sep 26. doi: 10.1002/ijc.30441.
    PubMed     Text format     Abstract available


  65. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
    PubMed     Text format     Abstract available


  66. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    PubMed     Text format     Abstract available


  67. KYRGIOU M, Kalliala I, Mitra A, Ng KY, et al
    Immediate referral to colposcopy vs. cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.
    Int J Cancer. 2016 Sep 7. doi: 10.1002/ijc.30419.
    PubMed     Text format     Abstract available


  68. CASTANON A, Landy R, Sasieni PD
    Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
    Int J Cancer. 2016;139:1040-5.
    PubMed     Text format     Abstract available


    August 2016
  69. VOLOSHIN T, Munster M, Blatt R, Shteingauz A, et al
    Alternating Electric Fields (TTFields) in Combination with Paclitaxel are Therapeutically Effective against Ovarian Cancer Cells in vitro and in vivo.
    Int J Cancer. 2016 Aug 25. doi: 10.1002/ijc.30406.
    PubMed     Text format     Abstract available


  70. SIMMS KT, Smith MA, Lew JB, Kitchener HC, et al
    Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
    Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30392.
    PubMed     Text format     Abstract available


  71. ISIDEAN SD, Mayrand MH, Ramanakumar AV, Gilbert L, et al
    Human Papillomavirus Testing versus Cytology in Primary Cervical Cancer Screening: End-of-Study and Extended Follow-Up Results from the Canadian Cervical Cancer Screening Trial (CCCaST).
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30385.
    PubMed     Text format     Abstract available


  72. CAMPBELL C, Kafwafwa S, Brown H, Walker G, et al
    Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi.
    Int J Cancer. 2016;139:908-15.
    PubMed     Text format     Abstract available


  73. SCHIFFMAN M, Hyun N, Raine-Bennett TR, Katki H, et al
    A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage.
    Int J Cancer. 2016 Aug 10. doi: 10.1002/ijc.30375.
    PubMed     Text format     Abstract available


  74. MARSHALL AD, van Geldermalsen M, Otte NJ, Anderson L, et al
    LAT1 is a Putative Therapeutic Target in Endometrioid Endometrial Carcinoma.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30371.
    PubMed     Text format     Abstract available


    July 2016
  75. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
    Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
    PubMed     Text format     Abstract available


  76. LEE AW, Bomkamp A, Bandera EV, Jensen A, et al
    A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.
    Int J Cancer. 2016 Jul 15. doi: 10.1002/ijc.30274.
    PubMed     Text format     Abstract available


    June 2016
  77. DEPUYDT CE, Thys S, Beert J, Jonckheere J, et al
    Linear viral load increase of a single HPV-type in women with multiple HPV infections predicts progression to cervical cancer.
    Int J Cancer. 2016 Jun 24. doi: 10.1002/ijc.30238.
    PubMed     Text format     Abstract available


  78. ALSINA-SANCHIS E, Figueras A, Lahiguera A, Vidal A, et al
    The TGFbeta pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
    Int J Cancer. 2016 Jun 14. doi: 10.1002/ijc.30233.
    PubMed     Text format     Abstract available


  79. ZHAO FH, Hu SY, Zhang Q, Zhang X, et al
    Risk assessment to guide cervical screening strategies in a large Chinese population.
    Int J Cancer. 2016;138:2639-47.
    PubMed     Text format     Abstract available


    May 2016
  80. OREN R, Addadi Y, Narunsky Haziza L, Dafni H, et al
    Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.
    Int J Cancer. 2016 May 31. doi: 10.1002/ijc.30209.
    PubMed     Text format     Abstract available


  81. KELLY Z, Moller-Levet C, McGrath S, Butler-Manuel S, et al
    The prognostic significance of specific HOX gene expression patterns in ovarian cancer.
    Int J Cancer. 2016 May 26. doi: 10.1002/ijc.30204.
    PubMed     Text format     Abstract available


  82. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
    Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
    PubMed     Text format     Abstract available


    April 2016
  83. TANG A, Dadaglio G, Oberkampf M, Di Carlo S, et al
    B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer.
    Int J Cancer. 2016 Apr 30. doi: 10.1002/ijc.30169.
    PubMed     Text format     Abstract available


  84. RADDE K, Gottschalk A, Bussas U, Schulein S, et al
    Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY Study.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30146.
    PubMed     Text format     Abstract available


  85. CIRILLO PM, Wang ET, Cedars MI, Chen LM, et al
    Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30144.
    PubMed     Text format     Abstract available


    March 2016
  86. EBISCH RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, et al
    The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30090.
    PubMed     Text format     Abstract available


    February 2016
  87. HERWEIJER E, Sundstrom K, Ploner A, Uhnoo I, et al
    Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2016 Feb 9. doi: 10.1002/ijc.30035.
    PubMed     Text format     Abstract available


  88. PETRY KU, Cox JT, Johnson K, Quint W, et al
    Evaluating HPV negative CIN2+ in the ATHENA trial.
    Int J Cancer. 2016 Feb 6. doi: 10.1002/ijc.30032.
    PubMed     Text format     Abstract available


  89. BHATIA R, Kavanagh K, Cubie H, Serrano I, et al
    Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.
    Int J Cancer. 2016 Feb 4. doi: 10.1002/ijc.30030.
    PubMed     Text format     Abstract available


    January 2016
  90. MOLIJN A, Jenkins D, Chen W, Zhang X, et al
    The complex relationship between human papillomavirus and cervical adenocarcinoma.
    Int J Cancer. 2016;138:409-16.
    PubMed     Text format     Abstract available


  91. STENSEN S, Kjaer SK, Jensen SM, Frederiksen K, et al
    Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.
    Int J Cancer. 2016;138:361-8.
    PubMed     Text format     Abstract available


  92. VAN BAARS R, van der Marel J, Snijders PJ, Rodriquez-Manfredi A, et al
    CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies.
    Int J Cancer. 2016;138:463-71.
    PubMed     Text format     Abstract available


    December 2015
  93. SKINNER SR, Wheeler CM, Romanowski B, Castellsague X, et al
    Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29971.
    PubMed     Text format     Abstract available


    September 2015
  94. ZHANG R, Shen C, Zhao L, Wang J, et al
    Dysregulation of host cellular genes targeted by HPV integration contributes to HPV related cervical carcinogenesis.
    Int J Cancer. 2015 Sep 29. doi: 10.1002/ijc.29872.
    PubMed     Text format     Abstract available


    January 2015
  95. VERDOODT F, Jiang X, Williams M, Schnatz PF, et al
    High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis.
    Int J Cancer. 2015 Jan 12. doi: 10.1002/ijc.29424.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: